Upcoming event

Non-muscle-invasive Bladder Cancer (TaT1 and CIS)

  • M. Babjuk
  • M. Burger
  • E. Compérat
  • P. Gontero
  • A.H. Mostafid
  • J. Palou
  • B.W.G. van Rhijn
  • M. Rouprêt
  • S.F. Shariat
  • R. Sylvester
  • R. Zigeuner
  • O. Capoun
  • D. Cohen
  • V. Hernández
  • V. Soukup
  • M. Babjuk
  • M. Burger
  • E. Compérat
  • P. Gontero
  • A.H. Mostafid
  • J. Palou
  • B.W.G. van Rhijn
  • M. Rouprêt
  • S.F. Shariat
  • R. Sylvester
  • R. Zigeuner
  • O. Capoun
  • D. Cohen
  • V. Hernández
  • V. Soukup

This 2019 NMIBC Guidelines document presents a limited update of the 2018 publication.

Summary of changes
Additional data has been included throughout this document text. In particular in sections:

  • Section 5.4.3 – Multiparametric magnetic resonance imaging (mpMRI);
  • Section 5.10.2 – Surgical and technical aspects of tumour resection: a new paragraph on TUR best practice has been included;

A new recommendation has been added to:

  • Section 5.14 – Summary of evidence and guidelines for transurethral resection of

the bladder, biopsies and pathology report
Section 7.3.2 – Recurrence and failure after intravesical bacillus Calmette-Guérin (BCG) immunotherapy: this section, including Table 7.2 (Categories of unsuccessful treatment with intravesical BCG) has beenexpanded.

Publication: European Association of Urology

Tags: Guidelines